Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area.
There is evidence that the kappa opioid system plays an important role in cocaine addiction and that chronic cocaine administration and withdrawal from chronic cocaine alter kappa opioid receptor (KOPr) density. The present study employed in situ [(35)S]guanosine 5'-O-[gamma-thio]triphosphate acid (GTPgammaS) binding autoradiography to measure KOPr-stimulated activation of G-protein in the caudate putamen, nucleus accumbens core and shell, lateral hypothalamus, basolateral amygdala, substantia nigra compacta, substantia nigra reticulata and ventral tegmental area (VTA), in response to chronic cocaine administration or acute and chronic withdrawal from chronic cocaine. Male Fischer rats were injected i.p. with saline or cocaine three times daily at 1 h intervals in an escalating-dose paradigm for 14 days (from 3x15 mg/kg/injection on days 1-3 up to 3x30 mg/kg/injection on days 10-14). Identically treated separate groups were withdrawn from cocaine or saline for 24 h or 14 days. No significant change in KOPr agonist U-69593-stimulated [(35)S]GTPgammaS was found in the seven regions studied 30 min or 14 days after chronic 14 days escalating-dose binge cocaine administration. However there was an increase in KOPr -stimulated [(35)S]GTPgammaS binding in the VTA (P<0.01) of rats withdrawn for 24 h from chronic cocaine. Our results show a cocaine withdrawal induced increase of KOPr signaling in the VTA, and suggest that the KOPr may play a role in acute withdrawal from cocaine.
Piras
A P
AP
The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Avenue, Box 171, New York, NY 10065, USA.
Zhou
Y
Y
Schlussman
S D
SD
Ho
A
A
Kreek
M J
MJ
D000818:Animals; D001345:Autoradiography; D044482:Benzeneacetamides / Q000494:pharmacology; D003042:Cocaine / Q000008:administration & dosage / Q000009:adverse effects*; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000378:metabolism*; D008297:Male; D011759:Pyrrolidines / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D011916:Rats, Inbred F344; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000502:physiology*; D013375:Substance Withdrawal Syndrome / Q000378:metabolism*; D013378:Substantia Nigra / Q000378:metabolism; D017557:Ventral Tegmental Area / Q000378:metabolism*
D044482:Benzeneacetamides; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D003042:Cocaine; C045444:U 69593
Psychopharmacology (Berl). 2007 Oct;194(3):361-9
17604981
Brain Res. 2003 Jun 6;974(1-2):249-53
12742644
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
2899326
J Comp Neurol. 1994 Dec 15;350(3):412-38
7884049
Synapse. 2002 Sep 15;45(4):220-9
12125043
Neuroreport. 1993 May;4(5):543-6
8099817
Nat Neurosci. 2005 Nov;8(11):1481-9
16251991
Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):258-62
15950784
Pharmacol Ther. 2007 Nov;116(2):306-21
17868902
Neuroscience. 1999;91(3):971-7
10391475
Neuroreport. 1994 Aug 15;5(13):1613-6
7819531
Psychopharmacology (Berl). 1989;98(2):203-6
2569217
Synapse. 2000 Sep 15;37(4):292-7
10891866
J Pharmacol Exp Ther. 1996 Apr;277(1):359-65
8613942
Brain Res Mol Brain Res. 1993 Sep;19(4):323-7
7694032
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2938-42
16477003
Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2046-50
1347943
J Comp Neurol. 1992 Feb 15;316(3):314-47
1577988
Synapse. 2003 Jan;47(1):26-32
12422370
J Pharmacol Exp Ther. 1993 Sep;266(3):1236-46
7690399
Jpn J Pharmacol. 1992 Apr;58(4):435-42
1328733
Brain Res Bull. 2000 Jul 1;52(4):297-302
10856828
Psychopharmacology (Berl). 2009 Sep;205(4):565-75
19484223
Rev Neurol (Paris). 1990;146(10):570-4
2263819
Psychopharmacology (Berl). 2002 Apr;161(1):17-22
11967626
J Pharmacol Exp Ther. 1999 May;289(2):607-24
10215631
Neurosci Biobehav Rev. 2006;30(2):126-47
16183121
Brain Res. 1991 Mar 15;543(2):227-35
1905576
Eur J Neurosci. 2003 May;17(10):2212-8
12786988
Nat Rev Drug Discov. 2002 Sep;1(9):710-26
12209151
Synapse. 2007 Oct;61(10):820-6
17621646
Eur J Neurosci. 2008 Aug;28(4):759-70
18671743
Pharmacol Biochem Behav. 1996 Jan;53(1):5-9
8848459
Neuroscience. 2000;101(3):619-27
11113311
Neuroscience. 1998 Aug;85(4):1051-9
9681945
Psychopharmacology (Berl). 2004 Apr;173(1-2):146-52
14712342
J Neurosci. 1999 May 15;19(10):4102-9
10234038
Brain Res Bull. 2005 Oct 15;67(3):169-75
16144651
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7242-6
7638174
Neuroscience. 2008 Jun 2;153(4):1225-34
18436386
Drug Alcohol Depend. 1998 Jun-Jul;51(1-2):13-22
9716927
J Pharmacol Exp Ther. 1994 Feb;268(2):916-21
8114005
Life Sci. 1991;48(21):1991-2003
1851914
J Neurochem. 1990 Sep;55(3):1079-82
2117048
Synapse. 1993 Apr;13(4):357-69
7683144
J Pharmacol Exp Ther. 1993 Jan;264(1):489-95
8093731
Am J Psychiatry. 2005 Aug;162(8):1403-13
16055761
Eur J Pharmacol. 2005 Oct 31;523(1-3):67-70
16226245
J Neural Transm Gen Sect. 1993;91(1):53-66
8383985